PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 113 products of "PD-1/PD-L1"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Durvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Purity:95% - 97.2% (SDS-PAGE); 95.3% (SEC-HPLC)Color and Shape:LiquidMolecular weight:146.03 kDaDostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Purity:>95%Color and Shape:LiquidMolecular weight:144.18 kDaBudigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.
Purity:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Color and Shape:LiquidSpartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Purity:SDS-PAGE:95.2%;SEC-HPLC:96.3%Color and Shape:LiquidMolecular weight:145.74 kDaSintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.
Purity:> 95%Color and Shape:LiquidMolecular weight:144.04 kDaAUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormula:C144H230N40O50Purity:95.07%Color and Shape:SolidMolecular weight:3321.61BMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormula:C35H35ClN2O7Purity:97.36%Color and Shape:SolidMolecular weight:631.11Ref: TM-T10565
1mg52.00€5mg120.00€10mg187.00€25mg380.00€50mg612.00€100mg973.00€200mg1,305.00€1mL*10mM (DMSO)169.00€Opamtistomig
CAS:Opamtistomig is a humanized monoclonal antibody immunoglobulin (H-γ1-scFv-L-κ) dimer targeting human programmed death-ligand 1 (PD-L1), CD274, and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). It is anticipated for use in research on various solid tumors and hematologic malignancies.Color and Shape:LiquidTQB-2858
TQB-2858 is a bifunctional fusion protein composed of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of the TGF-β receptor. It exhibits high affinity for PD-L1, TGF-β1, and TGF-β3, and demonstrates a high target occupancy rate for PD-L1. TQB-2858 can be used in research on osteosarcoma and alveolar soft part sarcoma (ASPS).Color and Shape:Odour LiquidPD-1/PD-L1-IN-49
PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 77 nM. This compound can activate Jurkat T cells and effectively block the PD-1/PD-L1 immune checkpoint.Formula:C27H32N4O5Color and Shape:SolidMolecular weight:492.567AUNP-12
CAS:AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.Formula:C142H226N40O48Purity:98%Color and Shape:SolidMolecular weight:3261.55Zeluvalimab
CAS:Zeluvalimab (AMG-404) is a monoclonal antibody designed to target the PD-1 receptor, and is utilized in cancer research [1].Color and Shape:LiquidPD-1/PD-L1-IN-50
Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.Color and Shape:Odour SolidPD-1/PD-L1-IN-51
PD-1/PD-L1-IN-51 (Compound III-4) is an inhibitor of PD-1/PD-L1 (IC50: hPD-L1 at 2.9 nM). It binds directly to PD-L1, blocking the interaction between PD-1 and PD-L1, and enhancing the release of IFN-γ. Additionally, PD-1/PD-L1-IN-51 exhibits antitumor activity.Color and Shape:Odour SolidPD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Color and Shape:Odour SolidSotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPurity:98%Color and Shape:SolidEciskafusp alfa
CAS:Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specificPurity:98%Color and Shape:SolidAnti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.Color and Shape:Odour LiquidHuman membrane-bound PD-L1 polypeptide
CAS:Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].Formula:C85H140N26O36SPurity:98%Color and Shape:SolidMolecular weight:2134.24H-20
CAS:H-20 is a PD-1 agonist that reduces the required dosage of morphine for analgesia. It can be used in studies related to chronic pain.Formula:C44H64N10O15Color and Shape:SolidMolecular weight:973.037Asudemotide
CAS:Asudemotide is a bioactive chemical.Formula:C58H80N10O17Purity:98%Color and Shape:SolidMolecular weight:1189.31HX009
HX009 is a bispecific antibody that targets PD1 and CD47, though its binding to CD47 is attenuated. HX009 functions by blocking PD1/CD47 and can be utilized in research related to non-Hodgkin lymphoma (NHL).Color and Shape:Odour LiquidGJ19
GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. It binds effectively to human and mouse PD-L1 proteins, exhibiting KD values of 171 nM and 290 nM, respectively. In a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells, GJ19 promotes HepG2 cell death in a concentration-dependent manner. In the B16-F10 melanoma mouse model, GJ19 demonstrates significant tumor growth inhibition. GJ19 is applicable in tumor immunotherapy research.Color and Shape:Odour SolidBAT-1306
BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. It is applicable for research in colorectal cancer and solid tumors.Color and Shape:Odour LiquidRTX-002
RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. This compound is applicable in the research of autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.Color and Shape:Odour LiquidPD-1/PD-L1-IN-40
PD-1/PD-L1-IN-40 (Compound EP16) is a PD-1/PD-L1 inhibitor. It effectively suppresses the production of exosomal PD-L1 with an IC50 of 0.108 μM. PD-1/PD-L1-IN-40 serves as a lead compound for the elimination of exosomal PD-L1 and is applicable in cancer research.Formula:C20H22N4O2Molecular weight:350.17428AM0001
AM0001 is a human monoclonal antibody (mAb) that targets PDCD1/PD-1/CD279. It is applicable in cancer research.Color and Shape:Odour LiquidGR-1405
GR-1405 is a human monoclonal antibody (mAb) that targets B7-H1/PD-L1/CD274. It enhances the antitumor immune response mediated by cytotoxic T lymphocytes (CTL) against tumor cells expressing PD-L1. GR-1405 is applicable in research related to lymphomas and solid tumors.Color and Shape:Odour LiquidRK-10
CAS:RK-10 is a peptide that binds to PD-L1. After being conjugated with Cy5 or Biotin, RK-10 can be used to identify PD-L1-expressing tumors through flow cytometry or immunohistochemistry. It is applicable for research in detecting cancers such as non-small cell lung cancer (NSCLC), breast cancer, squamous cell carcinoma, and melanoma.Formula:C105H176N28O36SColor and Shape:SolidMolecular weight:2438.75PMT-O9-1A
PMT-O9-1A is an effective PD-L1 degrader that reduces PD-L1 protein expression and exhibits cytotoxic properties. Additionally, PMT-O9-1A possesses anticancer activity.Formula:C22H25ClN2O4Color and Shape:SolidMolecular weight:416.90PD-1/PD-L1 inhibitory peptide C8
PD-1/PD-L1 inhibitory peptide C8 disrupts the PD-1/PD-L1 interaction, leading to the activation of CD8+ and CD4+ T cells and an increase in IFN-γ secretion. In mouse models, PD-1/PD-L1 inhibitory peptide C8 has demonstrated antitumor activity.Formula:C51H72N14O14S2Color and Shape:SolidMolecular weight:1169.33PROTAC PD-1/PD-L1 degrader-1
CAS:PROTAC PD-1/PD-L1 degrader-1, a Cereblon-based inhibitor, blocks PD-1/PD-L1 with 39.2 nM IC50, boosting immune response and reducing PD-L1 via lysosomes.Formula:C59H58ClN7O11Purity:99.07%Color and Shape:SolidMolecular weight:1076.59Human PD-L1 inhibitor V
CAS:Human PD-L1 Inhibitor V is a peptide that binds to the human PD-1 protein with an affinity characterized by a dissociation constant (Kd) of 3.32 μM, effectivelyFormula:C65H104N20O18SPurity:98%Color and Shape:SolidMolecular weight:1485.71Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
Anti-MousePD-1Antibody (D265A) is an antibody inhibitor targeting the PD-1 protein in mice.Color and Shape:Odour LiquidIparomlimab
CAS:Iparomlimab: anti-PD-1 IgG4κ antibody, targets PSB103 γ4/κ-chains, forms dimers, used in cancer research.Color and Shape:LiquidBalstilimab
CAS:Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 [1] .Color and Shape:LiquidEnlonstobart
CAS:Enlonstobart is a humanized IgG4-κ monoclonal antibody targeting PDCD1, functioning as both an immunostimulant and antineoplastic agent [1].Color and Shape:LiquidFinotonlimab
Finotonlimab (SCT-I10A), a humanized IgG PD-1 monoclonal antibody, shows potential in the research of solid tumors or lymphomas [1].Color and Shape:Odour LiquidManelimab
CAS:Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 ( PD-L1 ) [1] .Color and Shape:LiquidLatikafusp
CAS:Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.Purity:97.1% (SDS-PAGE); 97.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 97.4% (SEC-HPLC)Color and Shape:LiquidMolecular weight:159.55 kDaAtorolimumab
CAS:Atorolimumab (P3x22914G4), a monoclonal antibody, is employed in immunotherapies that target the programmed death-1 (PD-1) receptor [1].Color and Shape:LiquidLorigerlimab
CAS:Lorigerlimab (MGD019) is a bispecific IgG4 DART that blocks PD-1/CTLA-4, enhancing T-cells for mCRPC research.Color and Shape:LiquidRetifanlimab
CAS:Retifanlimab (MGA-012) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Retifanlimab is used in studies of Merkel cell carcinoma.Purity:98.56% (SEC-HPLC) - >95.0% (SDS-PAGE); 100% (SEC-HPLC)Color and Shape:LiquidMolecular weight:148.28 kDaIzuralimab
CAS:Izuralimab is a bispecific IgG1 antibody that targets both the inducible T-cell costimulator (ICOS/CD278) and PD-1 [1].Color and Shape:LiquidAnti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting and inhibiting mouse PD-L1/B7-H1.Color and Shape:Odour LiquidCAY10678
CAS:CAY10678 is an mPGES-1 inhibitor that inhibits PD-1.CAY10678 reduces collagen deposition and T-cell depletion, and may be used to study melanoma.CASHIPSFormula:C23H34N4OPurity:99.66%Color and Shape:SolidMolecular weight:382.542-Methylbiphenyl-oxadiazole-NH-Ph-CHO
CAS:2-Methylbiphenyl-oxadiazole-NH-Ph-CHO functions as a PD-L1 ligand for AUTACPD-L1degrader-3. It is also applicable in the synthesis of AUTAC.Formula:C22H17N3O2Color and Shape:SolidMolecular weight:355.392-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc
2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc is the PD-L1 ligand-linker polymer of AUTACPD-L1degrader-3. It can be utilized in the synthesis of AUTAC.Formula:C35H45N5O6Color and Shape:SolidMolecular weight:631.76LTB
LTB is a prodrug formed through the conjugation of the glycolysis inhibitor (Lonidamine) and the PD1/PDL1 blocker (BMS-1) via a thioketal bond. LTB can encapsulate the photosensitizer Chlorin e6 (Ce6), constructing a co-delivery photodynamic nanoplatfform through self-assembly (LTB-6 NPs).Formula:C53H59Cl2N3O7S2Color and Shape:SolidMolecular weight:985.09D5B
D5B is an effective and selective PD-L1 inhibitor that has been modified with DBCO. It degrades PD-L1 in 4T1 and B16-F10 tumor cells with EC50 values of 5.4 μM and 6.2 μM, respectively. D5B can block the PD-L1/PD-1 interaction and exhibits antitumor activity.Formula:C58H66N2O12Color and Shape:SolidMolecular weight:983.15Lon-TK
Lon-TK is a glycolysis inhibitor of LTB, linked with a linker conjugate. LTB is an intelligent responsive prodrug, comprised of Lonidamine (Lon) and a PD-L1 inhibitor (BMS-1), which are connected through a thioketal linkage. It effectively inhibits glycolytic metabolism in tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK holds potential for use in photodynamic-enhanced immunotherapy research.Formula:C24H28Cl2N2O3S2Color and Shape:SolidMolecular weight:527.53PD-1/PD-L1-IN-32
PD-1/PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1/PD-L1, displaying pronounced anticancer activity with an IC50 value of 2.4 nM.Purity:98%Color and Shape:Odour SolidPD-1/PD-L1-IN-31
PD-1/PD-L1-IN-31 is a potent inhibitor of PD-1/PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral bloodFormula:C24H24ClFN2O3Purity:98%Color and Shape:SolidMolecular weight:442.91(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysis-resistant D-peptide antagonist and a potent PD-1/PD-L1 inhibitor, exhibiting an affinity for PD-1 of 0.51 μM and demonstratingFormula:C72H99F3N20O23Purity:98%Color and Shape:SolidMolecular weight:1669.67LP23
LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/JurkatFormula:C27H27N3O5SPurity:98%Color and Shape:SolidMolecular weight:505.59IMMH 010 maleate
CAS:IMMH 010 maleate (YPD-30 maleate) is a programmed cell death ligand 1 inhibitor used in the study of neurological disorders and advanced malignant solid tumors.Formula:C36H36BrClN2O9Color and Shape:SoildMolecular weight:756.04ARB-272572 hydrochloride
CAS:ARB-272572 hydrochloride is a PD-L1 inhibitor that inhibits PD-1/PD-L1 cell signaling by inducing PD-L1 protein homology interactions.Formula:C32H36N6O4·xClHPurity:99.38%Color and Shape:SoildMolecular weight:568.68(Free base）PD-L1/VISTA-IN-2
PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.Formula:C22H22N2O3Color and Shape:SolidMolecular weight:362.42PD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formula:C22H24N2O2Purity:99.92%Color and Shape:SolidMolecular weight:348.44Ref: TM-T9651
1mg57.00€2mg85.00€5mg127.00€10mg178.00€25mg298.00€50mg405.00€100mg535.00€500mg1,063.00€1mL*10mM (DMSO)140.00€TPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formula:C109H151F3N34O34S2Color and Shape:SolidMolecular weight:2602.69PD-1/PD-L1-IN-48
PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.Color and Shape:Odour SolidHuman PD-L1 inhibitor I
CAS:Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Formula:C110H152N26O32Color and Shape:SolidMolecular weight:2350.576BMSpep-57
CAS:BMSpep-57: Macrocyclic peptide, inhibits PD-1/PD-L1, IC50=7.68 nM, binds PD-L1 (Kd=19 nM/MST, 19.88 nM/SPR), boosts T cell IL-2 in PBMCs.Formula:C89H126N24O19SColor and Shape:SolidMolecular weight:1868.2Human PD-L1 inhibitor II
CAS:Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Formula:C103H151N25O30Color and Shape:SolidMolecular weight:2219.486PD-L1 inhibitory peptide
CAS:PD-L1inhibitory peptide is an inhibitor peptide that targets the programmed cell death ligand 1 (PD-L1). By binding to PD-L1, it lifts immune suppression and restores the anti-tumor activity of T cells. PD-L1inhibitory peptide holds promise for use in tumor research.Formula:C96H135N21O23SColor and Shape:SolidMolecular weight:1983.29Human PD-L1 inhibitor IV
CAS:PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.Formula:C80H113N25O27Color and Shape:SolidMolecular weight:1856.932Human PD-L1 inhibitor III
CAS:Human PD-L1 inhibitor III is a human PD-L1 inhibitor.Formula:C97H155N29O29SColor and Shape:SolidMolecular weight:2223.54PD-L1-IN-5
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.
PD-1/PD-L1-IN-39
PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with an IC50 value of 15.73 nM. It exhibits strong binding affinity to human and mouse PD-L1, with KD values of 14.62 and 392 nM, respectively. PD-1/PD-L1-IN-39 also demonstrates antitumor activity.Formula:C23H20ClFN2O3Molecular weight:426.11465PROTAC PD-L1 degrader-1
PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.OPBP-1
OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.Formula:C64H92N20O19SMolecular weight:1476.65683Camrelizumab
CAS:Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up
Purity:95% - 98.6%Color and Shape:LiquidMolecular weight:143.7 kDaPacmilimab
CAS:Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.Purity:98.8% (SDS-PAGE); 96.3% (SEC-HPLC) - 98.8% (SDS-PAGE); 96.3% (SEC-HPLC)Color and Shape:LiquidProlgolimab
CAS:Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.Purity:>95%Color and Shape:LiquidMolecular weight:146.28 kDaN-deacetylated BMS-202
CAS:N-deacetylated BMS-202 is an inhibitor of PD-1/PD-L1 interaction with potential anticancer activity for cancer research.Formula:C23H27N3O2Purity:98.13% - 98.13%Color and Shape:SolidMolecular weight:377.48Pembrolizumab
CAS:Pembrolizumab (MK-3475) is a humanized monoclonal antibody.Cost-effective and quality-assured.Purity:95% - 99.70%Color and Shape:LiquidMolecular weight:149 kDaBMS-1166
CAS:BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.Formula:C36H33ClN2O7Purity:99.22%Color and Shape:SolidMolecular weight:641.11Ref: TM-T5697
1mg71.00€5mg146.00€10mg213.00€25mg406.00€50mg602.00€100mg893.00€200mg1,198.00€1mL*10mM (DMSO)197.00€Nivolumab
CAS:Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity. Cost-effective and quality-assured.Purity:98% - 98%Color and Shape:LiquidMolecular weight:143.62 kDaBMS-8
CAS:BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.Formula:C27H28BrNO3Purity:98.88%Color and Shape:SolidMolecular weight:494.42Ref: TM-T26859
1mg37.00€5mg79.00€10mg124.00€25mg222.00€50mg340.00€100mg505.00€200mg705.00€1mL*10mM (DMSO)86.00€BMS-1001
CAS:BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).Formula:C35H34N2O7Purity:98.43%Color and Shape:SolidMolecular weight:594.7Ref: TM-T8470
1mg58.00€5mg124.00€10mg177.00€25mg299.00€50mg424.00€100mg587.00€200mg792.00€1mL*10mM (DMSO)172.00€ARB-272572
CAS:ARB-272572 is a PD-L1 signaling inhibitor that produces immunostimulatory activity in human primary cells.Formula:C32H36N6O4Purity:97.36% - 98.07%Color and Shape:SolidMolecular weight:568.67Ref: TM-T39914
1mg123.00€5mg295.00€10mg425.00€25mg712.00€50mg1,035.00€100mg1,485.00€200mg1,998.00€1mL*10mM (DMSO)353.00€BMS-1166-n-piperidine-co-n-piperazine dihydrochloride
CAS:BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride is a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (Formula:C41H45Cl3N4O5Purity:98.94%Color and Shape:SoildMolecular weight:780.18Envafolimab
CAS:Envafolimab (ASC 22) is a humanized antibody targeting PD-L1, with anticancer activity, blocking the PD-L1 and PD-1 interaction.Purity:95%Color and Shape:LiquidMolecular weight:80 kDaSocazolimab
CAS:Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1 with antitumor activity, used in studies of recurrent or metastatic cervical cancer.Purity:95%Color and Shape:LiquidMolecular weight:143.06 kDaToripalimab
CAS:Toripalimab is a humanized anti-PD-1 monoclonal antibody used as an immune checkpoint inhibitor in research for advanced malignancies like nasopharyngeal carcinoma.Purity:95% - 95.2% (SDS-PAGE); 96.8% (SEC-HPLC)Color and Shape:LiquidTuvonralimab
CAS:Tuvonralimab, a combo of anti-PD-1/IgG4 and anti-CTLA-4/IgG1 antibodies, blocks dual immune checkpoints.Purity:95% - 95%Color and Shape:LiquidSugemalimab
CAS:Sugemalimab: human anti-PD-L1 IgG4 mAb with anticancer properties for non-small cell lung cancer.
Color and Shape:LiquidGilvetmab
CAS:Gilvetmab is a caninized anti-PD-1 antibody approved for veterinary use, researched for stage I-III mast cell tumors and stage II-III melanoma in dogs.Purity:95% - 97.9% (SDS-PAGE); 97.4% (SEC-HPLC)Color and Shape:LiquidMolecular weight:147.95 kDaAnti-Mouse/Human phosphorylated PD-1/CD279 Antibody
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is an IgG2a, κ antibody inhibitor derived from mice, targeting phosphorylated PD-1/CD279 in both mice and humans.Color and Shape:Odour LiquidAnti-Mouse PD-1 Antibody (S-5001)
Anti-MousePD-1Antibody (S-5001) is an IgG1 antibody inhibitor that targets mouse PD-1.Color and Shape:Odour LiquidRosnilimab
CAS:Rosnilimab is a PD-1 agonist that inhibits T cell proliferation and depletes T cells, enabling research into inflammatory diseases.Purity:95% - 98.9% (SDS-PAGE); 98.7% (SEC-HPLC)Color and Shape:LiquidMolecular weight:146.57 kDaReozalimab
CAS:Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, antitumour and enhances T-cell activation in vitro.Purity:95% - 98.1% (SDS-PAGE); 96.2% (SEC-HPLC)Color and Shape:LiquidMolecular weight:144.16 kDaAcasunlimab
CAS:Acasunlimab (GEN1046) is a bsAb that targets PD-L1 and 4-1BB, boosting T/NK cells and blocking PD-1/PD-L1 in cancer research.Color and Shape:LiquidLesabelimab
CAS:Lesabelimab (LDP) is an anti-CD274 monoclonal antibody of the immunoglobulin G1-kappa subclass.Color and Shape:LiquidPD-1/PD-L1-IN-20
CAS:PD-1/PD-L1-IN-20 is a small molecule inhibitor of PD-1/PD-L1 protein-protein interaction.Formula:C30H26BrClN2O3Color and Shape:SolidMolecular weight:577.9PD-1-IN-22
CAS:PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor(IC50 of 92.3 nM).Formula:C25H25N5O4Purity:99.51%Color and Shape:SolidMolecular weight:459.5Ref: TM-T12379
1mg109.00€2mg163.00€5mg243.00€10mg355.00€25mg532.00€50mg750.00€100mg1,009.00€500mg2,035.00€1mL*10mM (DMSO)284.00€PD-1/PD-L1-IN-NP19
CAS:PD-1/PD-L1-IN-NP19: a PD-1/PD-L1 inhibitor with 12.5 nM IC50, may boost antitumor immunity.Formula:C33H31ClN2O4Purity:96.70%Color and Shape:SolidMolecular weight:555.06PD-1/PD-L1-IN-27
CAS:PD-1/PD-L1-IN-27: potent anti-cancer, IC50 134nM, minimal T cell harm, boosts CD8+ T cells, reduces fatigue.Formula:C44H35NO6Purity:98%Color and Shape:SolidMolecular weight:673.75PD-1/PD-L1-IN-33
CAS:PD-1/PD-L1-IN-33 (Compound N11), a PD-1/PD-L1 inhibitor, effectively impedes the interaction between PD-1 and PD-L1 with an IC50 of 6.3 nM.Formula:C26H27N5OPurity:98%Color and Shape:SolidMolecular weight:425.53PD-1/PD-L1-IN-26
CAS:PD-1/PD-L1-IN-26 is a strong inhibitor with IC50 of 0.0380 μM that may boost immune response in cancer by aiding CD4+ T cell entry to tumors.Formula:C43H52N4O8Purity:98%Color and Shape:SolidMolecular weight:752.89
